Simultaneous hyperbaric oxygen therapy during systemic chemotherapy reverses chemotherapy-induced peripheral neuropathy by inhibiting TLR4 and TRPV1 activation in the central and peripheral nervous system
- 18 May 2021
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (11) , 6841-6850
Abstract
Background and objectives Chemotherapy-induced peripheral neuropathy (CIPN) is considered one of the most common sequelae in patients with cancer who experience consistent abnormal sensations or pain symptoms during or after paclitaxel (PAC) chemotherapy. Transient receptor potential vanilloid 1 (TRPV1) and toll-like receptor 4 (TLR4) have been reported to interact in the nervous system in patients with CIPN. The antinociceptive effects of hyperbaric oxygen therapy (HBOT) on CIPN was demonstrated in this study through behavior tests. Using a CIPN rat model, we examined the effects of simultaneous HBOT (SHBOT) administration during chemotherapy and discovered that SHBOT achieved better reversal effects than chemotherapy alone. Materials and methods Twenty-four rats were randomly allocated to four groups: control, PAC, SHBOT, and HBOT after PAC groups. Behavior tests were performed to evaluate mechanical allodynia and thermal hyperalgesia status. Tissues from the spinal cord and dorsal root ganglions were collected, and TLR4 and TRPV1 expression and microglial activation were investigated through immunofluorescence (IF) staining. Results The mechanical and thermal behavior tests revealed that HBOT intervention during PAC treatment led to the early alleviation of CIPN symptoms and inhibited CIPN deterioration. IF staining revealed that TLR4, TRPV1, and microglial activation were all upregulated in PAC-injected rats and exhibited early and significant downregulation in SHBOT-treated rats. Conclusion This study is the first to demonstrate that the use of SHBOT during PAC treatment has potential for the early suppression of CIPN initiation and deterioration, indicating that it can alleviate CIPN symptoms and may reverse CIPN in patients undergoing systemic chemotherapy.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (109-2314-B-037-020-MY3 and MOST109-2314-B-037-062)
- Kaohsiung Medical University Research Center Grant (KMU-TC108A02)
This publication has 50 references indexed in Scilit:
- Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritisPain, 2011
- Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancerInternational Journal of Clinical Oncology, 2011
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- LPS Sensitizes TRPV1 via Activation of TLR4 in Trigeminal Sensory NeuronsJournal of Dental Research, 2011
- Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary resultsInternational Journal of Hyperthermia, 2009
- An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the ratBrain Research, 2007
- Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumorsCancer Letters, 2004
- Transient Receptor Potential Vanilloid 4 Is Essential in Chemotherapy-Induced Neuropathic Pain in the RatJournal of Neuroscience, 2004
- Hyperbaric oxygen therapy in cluster headachePain, 1993
- Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicinPain, 1989